^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CCR8 inhibitor

    Related drugs:
    Apply
    Study of CHS-114 in Participants With Advanced Solid Tumors (SRF114-101) (NCT05635643)
    Phase 1
    Coherus Biosciences, Inc.
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    12/15/2022
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    PD-L1
    |
    CHS-114
    Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab (NCT05005403)
    Phase 1
    AbbVie
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    11/01/2021
    Primary completion :
    05/04/2026
    Completion :
    05/04/2026
    PD-L1
    |
    Keytruda (pembrolizumab) • budigalimab (ABBV-181) • ABBV-514
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (NCT05935098)
    Phase 1
    BeiGene
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    08/21/2023
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    CCR8
    |
    PD-L1 expression • CCR8 expression
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055